Conmed Corporation · NYSE:CNMD
Conmed — Q3 2025 Earnings Presentation
11 slides from Conmed's earnings presentation, Nov 5, 2025
Slide 1: Investor Presentation Q3 2025 Earnings
Investor Presentation Q3 2025 Earnings Pat J. Beyer President and Chief Executive Officer Todd W. Garner Executive Vice President and Chief Financial Officer November 5, 2025
Slide 2: Forward-Looking Information
Forward-Looking Information This presentation may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward- looking stateme
Slide 3: CONMED Vision
CONMED Vision Empower healthcare providers worldwide to deliver exceptional outcomes for patients. Focus behind the Vision People, Products, Profitability Q3 2025 Earnings Call 3
Slide 4: Objectives for Our Shareholders
Objectives for Our Shareholders • Aggregate growth and profitability over the long term to significantly increase the valuation of the company • Evolve product mix toward higher-growth, higher-margin offerings • Increase our market share in large and attractive markets • Deliver above-market revenue
Slide 5: Orthopedics: Large, Attractive Markets
Orthopedics: Large, Attractive Markets Dollar Value of 1 Market Category Description Market Size and Competitors Share Point $5.1 to $5.3 Billion Comprehensive portfolio of devices Sports for repair and healing of soft tissue ▪ Arthrex ▪ Zimmer Biomet Sept 2025 YTD ~$52M Medicine & injuries, includi
Slide 6: General Surgery: Large, Attractive Markets
General Surgery: Large, Attractive Markets Dollar Value of 1 Market Category Description Market Size and Competitors Share Point A platform of devices and accessories $1.5 to $1.7 Billion to create and enter the surgical ▪ Ethicon (J&J) ▪ Medtronic Access working space in minimally invasive ▪ Applie
Slide 7: Key Focus Areas: Q3 2025 Update
Key Focus Areas: Q3 2025 Update AirSeal – Clinical Insufflation Buffalo Filter – Smoke Evacuation • Clinical studies continue to highlight reduction in length of • Proprietary filtration technology continues to advance and stay and reduction in post-operative pain resonate with caregivers • Clinical
Slide 8: Q3 2025 Financial Performance
Q3 2025 Financial Performance Domestic Single-Use Products General Surgery $194.0M $289.2M $199.7M $337.9M Domestic 86% WW Orthopedic Surgery 57%/43% Single Use Capital Products International Revenue $138.2M International $143.9M Products $48.7M Worldwide CC Revenue Growth %* CC Revenue Growth %* Wo
Slide 9: September 2025 YTD Financial Performance
September 2025 YTD Financial Performance Domestic Single-Use Products General Surgery $568.3M $863.2M $584.3M $1,001.5M Domestic 86% WW Orthopedic Surgery 57%/43% Single Use Capital Products International Revenue $417.2M International $433.2M Products $138.3M Worldwide CC Revenue Growth %* CC Revenu
Slide 10: 2025 Updated Financial Guidance
2025 Updated Financial Guidance Original Updated Q1 Updated Q2 Updated Q3 Revenue Guidance Guidance Guidance Guidance Reported revenue $1,344 M to $1,372 M $1,350 M to $1,378 M $1,356 M to $1,378 M $1,365 M to $1,372 M Adjusted Diluted EPS Total $4.50 to $4.67 $4.60 to $4.70 $4.59 to $4.74 $4.67 to
Slide 11: Environmental, Social and Governance
Environmental, Social and Governance Together We Are Making A Difference for a Better Tomorrow View CONMED’s full 2024 ESG Report on CONMED.com Environmental Social Governance CONMED manufacturing operations Partners with the United Way to serve In addition to oversight by the full have recycling pr